Bilateral breast cancer: analysis of incidence, outcome, survival and disease characteristics
Kheirelseid, Elrasheid A. H.
Kerin, Michael J.
MetadataShow full item record
This item's downloads: 0 (view details)
Cited 92 times in Scopus (view citations)
Kheirelseid, Elrasheid A. H. Jumustafa, Hanzali; Miller, Nicola; Curran, Catherine; Sweeney, Karl; Malone, Carmel; McLaughlin, Ray; Newell, John; Kerin, Michael J. (2010). Bilateral breast cancer: analysis of incidence, outcome, survival and disease characteristics. Breast Cancer Research and Treatment 126 (1), 131-140
There has been conflicting evidence on the impact of bilateral breast cancer (BBC) on the survival and management of patients. The objectives of this study were to address the incidence of BBC and to investigate its characteristics and outcome compared to unilateral cancer. Data were acquired from the prospectively maintained NUIG breast cancer database between 1988 and 2008. BBC were then categorized as synchronous (within 12 months) or metachronous (after 12 months of first tumour). SPSS was used for data analysis. The incidence of BBC in our population was 4.4% (112 of 2,524). Of those 2.1% were synchronous while 2.3% were metachronous. Compared to unilateral cases, bilateral cancer patients were younger (P = 0.021) and had smaller size (P = 0.001) and earlier stage (P &lt; 0.001) tumours at diagnosis. We identified the HER2/neu positivity as a risk factor for developing contralateral breast tumour and ER negativity as a risk factor for developing metachronous tumours. While there was no significant difference in survival for patients with bilateral compared to unilateral tumour (P &gt; 0.05), the synchronous tumour was associated with poorer survival (P = 0.010) in comparison to metachronous tumour. This large single-institutional experience does not support the increasing practice of prophylactic mastectomy but does justify regular follow-up with mammography for early detection of contralateral tumour.
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivs 3.0 Ireland
Showing items related by title, author, creator and subject.
Mcinerney, Niall; Colleran, Gabrielle; Rowan, Andrew; Walther, Axel; Barclay, Ella; Spain, Sarah; Jones, Angela M.; Tuohy, Stephen; Curran, Catherine; Miller, Nicola; Kerin, Michael; Tomlinson, Ian; Sawyer, Elinor (Springer Nature, 2008-11-13)Large scale association studies have identified low penetrance susceptibility alleles that predispose to breast cancer. A locus on chromosome 8q24.21 has been shown to harbour variants that predispose to breast, ovarian, ...
Systemic mirna-195 differentiates breast cancer from other malignancies and is a potential biomarker for detecting noninvasive and early stage disease Heneghan, H. M.; Miller, N.; Kelly, R.; Newell, J.; Kerin, M. J. (Alphamed Press, 2010-06-24)Purpose. The potential of microRNAs (miRNAs) as novel tumor markers has been the focus of recent scrutiny because of their tissue specificity, stability, and association with clinicopathological parameters. Data have emerged ...
Gene expression profiles of no- and hno-donor treated breast cancer cells: insights into tumor response and resistance pathways Cheng, Robert Y.S.; Basudhar, Debashree; Ridnour, Lisa A.; Heinecke, Julie L.; Kesarwala, Aparna H.; Glynn, Sharon; Switzer, Christopher H.; Ambs, Stefan; Miranda, Katrina M.; Wink, David A. (Elsevier BV, 2014-12-01)Nitric oxide (NO) synthase 2 (NOS2), a major inflammatory protein, modulates disease progression via NO in a number of pathologies, including cancer. The role of NOS2-derived NO is not only flux-dependent, which is higher ...